Revelation Biosciences, Inc. said it may use social media channels to communicate material information and comply with Regulation FD, while clarifying that such disclosures are neither furnished nor filed under the Securities Exchange Act of 1934.
REVB · Revelation Biosciences, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for September 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Nov 5, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 31%
- Latest filing
- 10-Q · Nov 5
- Price history
- Nov 2020 to Nov 2026
Latest documents
Revelation Biosciences, Inc. reported $9.1 million in cash as of September 30, 2026 and, based on current operating plans and projections, believes it can fund operations into the second quarter of 2027; nine-month net loss was $9.6 million.
Revelation says cash is insufficient, raising substantial going-concern doubt, with $9.1 million available and a $59.1 million deficit as of September 30, 2026; Nasdaq delisting is possible if market value stays below $5 million for 30 consecutive business days.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
REVB
this stock
Revelation Biosciences, Inc.
|
$2.52M | — | — | — | 1.9% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 13, 2026
- This year
- 22
Revelation Biosciences, Inc. said it may use social media channels to communicate material information and comply with Regulation FD, while clarifying that such disclosures are neither furnished nor filed under the Securities Exchange Act of 1934.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| REVB | -15.8% | +0.3% | -51.6% | -8.4% | +15.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | -10.3% | +6.6% | -46.0% | -3.2% | +10.3% |